These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 35328527)

  • 1. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
    Androutsakos T; Nasiri-Ansari N; Bakasis AD; Kyrou I; Efstathopoulos E; Randeva HS; Kassi E
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Goulas A; Polyzos SA
    Eur J Pharmacol; 2021 Sep; 907():174272. PubMed ID: 34147478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
    Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
    Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease.
    Chrysavgis L; Papatheodoridi AM; Chatzigeorgiou A; Cholongitas E
    J Gastroenterol Hepatol; 2021 Apr; 36(4):893-909. PubMed ID: 33439540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review.
    Xu R; Lian D; Xie Y; Chen Z; Wang Y; Mu L; Wang Y; Zhang B
    Front Biosci (Landmark Ed); 2023 Jul; 28(7):134. PubMed ID: 37525911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
    Ala M
    Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmented duodenal levels of sodium/glucose co-transporter 1 are associated with higher risk of nonalcoholic fatty liver disease and noninvasive index of liver fibrosis.
    Fiorentino TV; De Vito F; Suraci E; Marasco R; Catalano F; Andreozzi F; Hribal ML; Luzza F; Sesti G
    Diabetes Res Clin Pract; 2022 Mar; 185():109789. PubMed ID: 35192912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
    Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal studies of sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Makri E; Goulas A; Xanthopoulos K; Polyzos SA
    Ann Gastroenterol; 2024; 37(3):280-290. PubMed ID: 38779641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
    Dobbie LJ; Cuthbertson DJ; Hydes TJ; Alam U; Zhao SS
    Eur J Endocrinol; 2023 Jun; 188(6):K33-K37. PubMed ID: 37343141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
    Vincent RK; Williams DM; Evans M
    Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
    Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
    World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal, Metabolic and Hemodynamic Adaptations to Glycosuria in Type 2 Diabetes Patients Treated with Sodium-Glucose Co-Transporter Inhibitors.
    Cersosimo E; Miles JM
    Curr Diabetes Rev; 2019; 15(4):314-327. PubMed ID: 30101716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.